Company: SCLXW
Filing Date: 2025-02-27
Form Type: 8-K
Source: 0001193125-25-039211
Chunk: 0

Company: Scilex Holding Co
Filing Date: 2025-02-27
Form: 8-K
Item: Item 9.01
Chunk 0
---
Item 9.01.      Financial Statements and Exhibits.  

(d) Exhibits.

  Exhibit      Description                                                                                                                            
                                                                                                                                                      
  Number                                                                                                                                              
  10.1#        License Agreement (ZTlido), dated February 22, 2025, by and between Scilex Pharmaceuticals Inc. and RoyaltyVest Ltd.                   
  10.2         Parent Guarantee for Lidocaine License Agreement, dated February 22, 2025, by and between Scilex Holding Company and RoyaltyVest Ltd.  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  104          Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).                                  

  Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601. The Registrant agrees to furnish a copy of all omitted exhibits and schedules...  

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  SCILEX HOLDING COMPANY                                             
  By:                         /s/ Jaisim Shah                        
  Name:                       Jaisim Shah                            
  Title:                      Chief Executive Officer and President  

Date: February 27, 2025